Trevena Inc.
This article was originally published in Start Up
Executive Summary
Trevena has carved out a niche in seeking so-called 'biased ligands'--GPCR-binding compounds that selectively activate just one (or a few) of the many biological pathways mediated via a particular GPCR complex. By identifying a ligand that hits the pathways responsible for a medicine's benefits, and avoiding those behind the ill effects, the company hopes to develop safer and more effective therapies, initially in CNS and cardiovascular disease.
You may also be interested in...
With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.
With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.
Start-Up Previews (02/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.